Interpace Biosciences
(OTC) IDXG
Interpace Biosciences Financials at a Glance
Market Cap
$45.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$36.25M
Net Income (TTM)
$23.65M
EPS (TTM)
$0.73
P/E Ratio
2.24
Dividend
$0.00
Beta (Volatility)
0.61 (Low)
Dividend
$0.00
Beta (Volatility)
0.61 (Low)
Price
$1.64
Volume
4,640
Open
$1.65
Price
$1.64
Volume
4,640
Open
$1.65
Previous Close
$1.64
Daily Range
$1.60 - $1.65
52-Week Range
$0.76 - $2.40
Estimated Earnings Date
May 7, 2026
Dividend
$0.00
Beta (Volatility)
0.61 (Low)
Price
$1.64
Volume
4,640
Open
$1.65
Previous Close
$1.64
Daily Range
$1.60 - $1.65
52-Week Range
$0.76 - $2.40
Estimated Earnings Date
May 7, 2026
IDXG News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Interpace Biosciences
Industry
Healthcare Providers and Services
Sector
Health CareEmployees
102
CEO
Thomas W. Burnell, PhD
Website
www.interpacediagnostics.comHeadquarters
Parsippany, NJ 07054, US
IDXG Financials
Key Financial Metrics (TTM)
Gross Margin
62.53%
Operating Margin
9.32%
Net Income Margin
65.25%
Return on Equity
215.31%
Return on Capital
17.34%
Return on Assets
70.79%
Earnings Yield
44.64%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$45.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
27.70M
Volume
4.64K
Avg. Volume
6.14K
Financials (TTM)
Gross Profit
$22.66M
Operating Income
$3.38M
EBITDA
$4.07M
Operating Cash Flow
$4.88M
Capital Expenditure
-$497.00K
Free Cash Flow
$4.38M
Cash & ST Invst.
$2.65M
Total Debt
$1.08M
Interpace Biosciences Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$9.03M
-21.6%
Gross Profit
$5.90M
-19.9%
Gross Margin
65.37%
N/A
Market Cap
$45.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$409.27K
N/A
Employees
111
N/A
Net Income
$721.00K
-56.2%
EBITDA
$1.35M
-33.9%
Quarterly Fundamentals
Total Cash
$2.65M
+121.3%
Total Debt
$1.08M
-74.5%
Accounts Receivable
$5.93M
-32.4%
Inventory
$961.00K
-20.5%
Long Term Debt
$635.00K
-41.2%
Short Term Debt
$445.00K
-85.9%
Return on Assets
70.79%
N/A
Return on Invested Capital
11.47%
N/A
Free Cash Flow
$142.00K
-88.5%
Operating Cash Flow
$283.00K
-77.1%